Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Qiu, Lin ^a   Fu, Fangmeng ^b   Huang, Meng ^c   Lin, Yuxiang ^b   Chen, Yazhen ^a   Chen, Minyan ^b   Wang, Chuan ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUZHOU UNIVERSITY   (China)

^c Fujian Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; BREAST TUMOR; DISEASE FREE SURVIVAL; EVALUATION STUDY; FEMALE; HUMAN; META ANALYSIS; MORTALITY; OVARY; PATHOPHYSIOLOGY; PREMENOPAUSE; RISK FACTOR; SURVIVAL RATE;

ADULT; AGE FACTORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARY; PREMENOPAUSE; RISK FACTORS; SURVIVAL RATE;

EID: 84971260968     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26627     Document Type: Article

References (33)

1. Buzdar, A. U. & Hortobagyi, G. Update on endocrine therapy for breast cancer. Clinical Cancer Research 4, 527-534 (1998).
2. Powles, T. J. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 340, 1145-1147 (1992).
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351, 1451-1467 (1998).
4. Fisher, B., Digman, J., Bryant, J., DeCillis, A., Wickerham, D. L. et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88, 1529-1542 (1996).
5. Fisher, B. et al. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90, 1371-1388 (1998).
6. Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A. & Hortobagyi, G. N. Use of tamoxifen for breast cancer. Twenty-eight years later. J Clin Oncol 13, 513-529 (1995).
7. Baum, M. et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002).
8. Goss, P. E. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349, 1793-1802 (2003).
9. Coombes, R. C. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350, 1081-1092 (2004).
10. Coates, A. S. et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of Study BIG 1-98. J Clin Oncol 25, 486-492 (2007).
11. Tan, S. H. & Wolff, A. C. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Clin Breast Cancer 7, 455-464 (2007).
12. Clarke, M. J. Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. BMJ. 317, 1246-1248 (1998).
13. LHRH-agonists in Early Breast Cancer Overview Group et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 369, 1711-1723 (2007).
14. Wu, S. et al. Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study. Cancer Biother Radiopharm 28, 697-702 (2013).
15. Jonat, W. Luteinizing hormone-releasing hormone analogues the rationale for adjuvant use in premenopausal women with early breast cancer. Br J Cancer 78 Suppl 4, 5-8 (1998).
16. Davidson, N. E. et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT0101(E5188). J Clin Oncol. 23, 5973-5982 (2005).
17. Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 360, 679-691 (2009).
18. Tevaarwerk, A. J. et al. Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 32(35), 3948-3958 (2014).
19. Zhou, J. et al. Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor- Positive Breast Cancer without Chemotherapy-Induced Amenorrhea. Cancer Res Treat 47(1), 55-63 (2015).
20. Francis, P. A. et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 372(17), 1673 (2015).
21. The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results From the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. J Natl Cancer Inst 99, 516-525 (2007).
22. Arriagada, R. et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Annals of Oncology 16, 389-396 (2005).
23. Kaufmanna, M. et al. A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. European Journal of Cancer 43, 2351-2358 (2007).
24. Karlsson, P. et al. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Annals of Oncology 22, 2216-2226 (2011).
25. Kim, J. Y. et al. Ovarian function preservation with GnRH agonist in young breast cancer patients: Does it impede the effect of adjuvant chemotherapy? The Breast 23, 670-675 (2014).
26. Rivkin, S. E. et al. Adjuvant CMFVP Versus Adjuvant CMFVP Plus Ovariectomy for Premenopausal, Node-Positive, and Estrogen Receptor-Positive Breast Cancer Patients: A Southwest Oncology Group Study. Journal of Clinical Oncology 14, 46-51 (1996).
27. Baum, M. et al. Adjuvant goserelin in pre-menopausal patients withearly breast cancer: Results from the ZIPP study. European Journal of Cancer 42, 895-904 (2006).
28. Yang, H. et al. Combined effects of goserelin and tamoxifenon estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial. British Journal of Cancer 109, 582-588 (2013).
29. Desmedt, C. et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. Clin Cancer Res 14(16), 5158-5165 (2008).
30. Coates, A. S. et al. Tailoring therapies - improving the management of early breast cancer: St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 26(8), 1533-46 (2015).
31. Goldhirsch, A. et al. Adjuvant Therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst Monogr. 30, 44-51 (2001).
32. International Breast Cancer Study Group (IBCSG) et al. Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. J Natl Cancer Inst. 95(24), 1833-1846 (2003).
33. Jadad, A. R. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1-12 (1996).